The comparison of the effectiveness of lincocin® and azitro® in the treatment of COVID-19-associated pneumonia: A prospective study

Main Article Content

Oguz Guvenmez
Hüseyin Keskin
Burak Ay
Suayip Birinci
Muhammed Furkan Kanca

Keywords

coronavirus, pneumonia, treatment, COVID-19, medication

Abstract

The COVID-19 virus has spread rapidly around the world and there are many patients in multiple countries. Great efforts have been made to find effective medications against the COVID-19. This study aims to compare the effectiveness of LINCOCIN® and AZITRO® in the treatment of COVID-19 associated pneumonia. A total of 24 hospitalized patients aged between 30-80 years who were admitted to the Tarsus Medical Park Hospital between February to March 2020 was included in the study. The patients were divided into LINCOCIN® and AZITRO® treatment groups. Bronchoalveolar-lavage PCR results were compared after treatment. The mean age was 58.4±15.4 years in the LINCOCIN® group and 59.1±16.6 years in the AZITRO® group. In the LINCOCIN® group, the rate of males was 66.7% and it was 58.3% in the AZITRO® group. There were no statistical differences in terms of age and gender between the groups. On the 6th day after starting treatment, negative bronchoalveolar PCR result was 83.3% in the LINCOCIN® group and 33.3% in the AZITRO® group. The negative bronchoalveolar PCR proportion was significantly higher in the LINCOCIN® group than in the AZITRO® group. LINCOCIN® usage may be more appropriate in the treatment of COVID-19 associated pneumonia. Further studies with a large sample size should clarify these results.
Abstract 1185 | PDF Downloads 299 HTML Downloads 21 XML Downloads 0

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.105924

2. Wang L, Wang Y, Ye D, Liu Q. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020:105948. https://doi.org/10.1016/j.ijantimicag.2020.105948

3. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA – J Am Med Assoc. 2020;323(13):1239–42. https://doi.org/10.1001/jama.2020.2648

4. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. 2020. https://doi.org/10.1002/jmv.25783 [Online ahead of print]

5. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): A review of clinical features, diagnosis, and treatment. Cureus. 2020;12(3):e7355. https://doi.org/10.7759/cureus.7355

6. LINCOCIN® (lincomycin HCl) | Pfizer Medical Information – US [Internet]. [cited 2020 Apr 10]. Available from: https://www.pfizermedicalinformation.com/en-us/lincocin

7. Lincocin – FDA prescribing information, side effects and uses [Internet]. [cited 2020 Apr 10]. Available from: https://www.drugs.com/pro/lincocin.html

8. Azithromycin (Systemic) (Professional Patient Advice) – Drugs.com [Internet]. [cited 2020 Apr 10]. Available from: https://www.drugs.com/ppa/azithromycin-systemic.html

9. Azithromycin – Wikipedia [Internet]. [cited 2020 Apr 10]. Available from: https://en.wikipedia.org/wiki/Azithromycin

10. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

11. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3. https://doi.org/10.5582/bst.2020.01047

12. Molina JM, Delaugerre C, Goff J Le, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Médecine Mal Infect. 2020;50(4):384. https://doi.org/10.1016/j.medmal.2020.03.006

13. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(February):1–10. https://doi.org/10.3785/j.issn.1008-9292.2020.03.03

14. Li JW, Xin ZT, Wang XW, Zheng JL, Chao FH. Mechanisms of inactivation of hepatitis a virus in water by chlorine dioxide. Water Res. 2004;38(6):1514–19. https://doi.org/10.1016/j.watres.2003.12.021

15. Engelbrecht RS, Weber MJ, Salter BL, Schmidt CA. Comparative inactivation of viruses by chlorine. Appl Environ Microbiol. 1980;40(2):249–56. https://doi.org/10.1128/aem.40.2.249-256.1980

16. Morokutti-Kurz M, Graf C, Prieschl-Grassauer E. Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat. Int J Gen Med. 2017;10:53–60. https://doi.org/10.2147/IJGM.S120665

17. Oxford JS, Lambkin R, Gibb I, Balasingam S, Chan C, Catchpole A. A throat lozenge containing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncytial virus, influenza A and SARS-CoV. Antivir Chem Chemother. 2005;16(2):129–34. https://doi.org/10.1177/095632020501600205

18. Rabenau HF, Kampf G, Cinatl J, Doerr HW. Efficacy of various disinfectants against SARS coronavirus. J Hosp Infect. 2005;61(2):107–11. https://doi.org/10.1016/j.jhin.2004.12.023